{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T14:10:08Z","timestamp":1722262208686},"reference-count":25,"publisher":"American Psychiatric Association Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[1964,8]]},"DOI":"10.1176\/ajp.121.2.185","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T18:28:50Z","timestamp":1418840930000},"page":"185-187","source":"Crossref","is-referenced-by-count":1,"title":["TRANSIENT TOXICITY WITH CARPHENAZINE HYDROCHLORIDE"],"prefix":"10.1176","volume":"121","author":[{"given":"J.","family":"MENDELS","sequence":"first","affiliation":[{"name":"Registrar in Neuro-Psychiatry, Tara Hosptial for Nervous and Mental Diseases and University of the Witwatersrand, P.O. Box 13, Saxonwold, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"230","reference":[{"key":"p_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4691.1250"},{"key":"p_2","volume-title":"Yearbook of Dermatology","author":"Baer R. L.","year":"1958"},{"key":"p_3","volume-title":"Yearbook of Dermatology","author":"Baer R. L.","year":"1962"},{"key":"p_4","first-page":"437","volume":"5093","author":"Brit","year":"1958","journal-title":"Med. J."},{"key":"p_5","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1955.03730350056010"},{"key":"p_6","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1961.01580080005001"},{"key":"p_7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1958.tb13304.x"},{"key":"p_8","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1963.01590200090018"},{"key":"p_9","first-page":"257","volume":"13","author":"Spitzer R.","year":"1962","journal-title":"Hautarzt"},{"key":"p_10","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1950.52"},{"key":"p_14","unstructured":"ported as a useful drug in the treatment of schizophrenia, especially for the chronic schizophrenic( 1-3). The relative absence of side effects has been noted."},{"key":"p_15","unstructured":"Sainz(4) conducted a careful study of a group of patients who received no less than 150 mg. carphenazine for a minimum of 6 months. Six patients received a total daily dosage of 1-6 gm. He found no hepatic or blood abnormalities."},{"key":"p_16","volume-title":"et at., report on \"liver dysfunction","author":"There"},{"key":"p_17","volume-title":"P.O. Box 13, Saxonwold","author":"Registrar"},{"key":"p_20","unstructured":"Method. In the course of treating 12 consecutive patients with carphenazine (100-200 mg. daily) fortnightly full blood counts, urinanalyses and liver function tests were done over a period of 4-6 months. The latter included transaminases (S.G.O.T., S.G.P.T. and lactic dehydrogenose), turbidity and flocculation tests, and alkaline phosphatase."},{"key":"p_22","unstructured":"She was a 43-year-old paranoid schizophrenic who was on 25-50 mg. q.i.d. for #{149} -a SM = SM SI."},{"key":"p_97","unstructured":"Four patients who developed signs of hepatic and haematological toxicity while being treated with carphenazine hydrochloride are reported. The drug was stopped in one patient and continued in 3. All signs of toxicity disappeared in 12-16 weeks, without any reduction in dosage."},{"key":"p_98","first-page":"46","volume":"22","author":"Cacioppo J.","year":"1961","journal-title":"Dis. New. Syst."},{"key":"p_99","first-page":"37","volume":"22","author":"Oltman J. E.","year":"1961","journal-title":"Dis. New. Syst."},{"key":"p_100","first-page":"80","volume":"22","author":"Tobian J. M.","year":"1961","journal-title":"Dis. New. Syst."},{"key":"p_101","first-page":"28","volume":"22","author":"Sainz A.","year":"1961","journal-title":"Dis. New. Syst."},{"key":"p_102","volume-title":"ibid., 22: 7","author":"Tislow R.","year":"1961"},{"key":"p_106","unstructured":"Concern about the possible long-range toxic effects of the psychotropic agents has been evident since their introduction in the early 1950's. A recent report by Greiner and Berry 2 brings to light additional reasons for maintaining vigilance and concern. They report 70 patients (\"from many thousands receiving similar therapy\") who developed peculiar pigmentation of the skin, cornea and lens following prolonged treatment with chlorpromazine (3-5 years) at doses of 500 to 1,500 mg. daily."},{"key":"p_108","first-page":"663","volume":"90","author":"Greiner A. C.","year":"1964","journal-title":"Canad. Med. Ass. J."},{"key":"p_110","volume-title":"single, white female who was admitted in 1944 with a diagnosis of schzophrenic reaction, catatonic type, acute. Her hospitalization has been uninterrupted to date. She first received chlorpromazine","author":"The","year":"1954"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/ajp.121.2.185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T13:57:17Z","timestamp":1722261437000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/ajp.121.2.185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1964,8]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1964,8]]}},"alternative-id":["10.1176\/ajp.121.2.185"],"URL":"https:\/\/doi.org\/10.1176\/ajp.121.2.185","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[1964,8]]}}}